Compass-logo-RGB-outlines.png
Compass Therapeutics Reports 2024 Second Quarter Financial Results and Provides Corporate Update
August 12, 2024 08:00 ET | Compass Therapeutics
Compass Therapeutics announces 2nd quarter results and provides clinical results update
Compass-logo-RGB-outlines.png
Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update
March 21, 2024 09:00 ET | Compass Therapeutics
Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update
Compass-logo-RGB-outlines.png
Compass Therapeutics Reports First Quarter Financial Results and Provides Corporate Update
May 04, 2023 08:30 ET | Compass Therapeutics
Initiated patient enrollment in a U.S. Phase 2/3 study of CTX-009 (DLL4 /VEGF-A bispecific antibody) in patients with advanced biliary tract cancers (BTC). Top line data is expected in the first half...
Compass-logo-RGB-outlines.png
Compass Therapeutics Announces that the Phase 2 Data of CTX-009 in Combination with Paclitaxel in Patients with Biliary Tract Cancers (BTC) will be Presented at the ASCO GI Cancers Symposium on January 20, 2023
January 19, 2023 17:00 ET | Compass Therapeutics
Compass to Host Investor Event on Monday, January 23rd at 8:30am ET CTX-009 in combination with paclitaxel demonstrated a 37.5% overall response rate (ORR) in 24 patients with BTC treated in the...
Persistence Market Research
Vascular Endothelial Growth Factor (VEGF) Market growth estimated CAGR of 10.7% for the next ten years (2022-2032) – Persistence Market Research
July 05, 2022 09:00 ET | Persistence Market Research
New York, July 05, 2022 (GLOBE NEWSWIRE) -- Growing significance of genomics and proteomics has been contributing to the growth of the global vascular endothelial growth factor (VEGF) market. The...
Compass-logo-RGB-outlines.png
Compass Therapeutics to Present at the 2022 H.C. Wainwright Annual Global Investment Conference
May 23, 2022 08:00 ET | Compass Therapeutics
BOSTON, May 23, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer,...
Compass-logo-RGB-outlines.png
Compass Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress
May 09, 2022 08:00 ET | Compass Therapeutics
The FDA cleared the investigational new drug application for CTX-009 (DLL4 X VEGF-A bispecific) in January allowing the Company to expand the ongoing Phase 2 study in patients with biliary tract...
Compass-logo-RGB-outlines.png
Compass Therapeutics Reports Positive Interim Phase 2 Data of CTX-009 in Combination with Paclitaxel in Biliary Tract Cancers
May 04, 2022 07:00 ET | Compass Therapeutics
CTX-009 Demonstrated a 42% Overall Response Rate (ORR) Based on 10 Partial Responses (PRs) in 24 Enrolled Patients CTX-009 Continues to be Well Tolerated, Consistent with the Phase 1 Studies ...
Compass-logo-RGB-outlines.png
Compass Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
March 21, 2022 08:00 ET | Compass Therapeutics
Ended 2021 with $144.5 million in cash and cash equivalentsCTX-009 (DLL4 X VEGF-A bispecific antibody) Global Phase 2 study in patients with advanced biliary tract cancers (BTC) is progressing well;...
Compass-logo-RGB-outlines.png
Compass Therapeutics Announces US FDA Clearance of Investigational New Drug Application for a Phase 2 Study of CTX-009, a Bispecific Antibody That Simultaneously Targets Delta-like Ligand 4 (DLL4) and Vascular Endothelial Growth Factor A (VEGF-A)
January 20, 2022 08:30 ET | Compass Therapeutics
BOSTON, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer,...